key: cord-0746616-xpd88drz
authors: Dorgham, Karim; Neumann, Avidan U.; Decavele, Maxens; Luyt, Charles-Edouard; Yssel, Hans; Gorochov, Guy
title: Considering Personalized Interferon Beta Therapy for COVID-19
date: 2021-03-18
journal: Antimicrob Agents Chemother
DOI: 10.1128/aac.00065-21
sha: 579a23dcf287a989cbdcbf8de80e7ca860f0329d
doc_id: 746616
cord_uid: xpd88drz

Davoudi-Monfared et al. (1) report in this Journal the results from a clinical trial on COVID-19 patients showing that subcutaneous administration of interferon-β (IFN-β) was associated with a more rapid recovery from SARS-CoV-2 infection and decreased mortality.….

D avoudi-Monfared et al. (1) report in this journal the results from a clinical trial on coronavirus disease 2019 (COVID-19) patients showing that subcutaneous administration of interferon beta (IFN-b) was associated with a more rapid recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and decreased mortality. These findings have been corroborated by two recent phase 2 clinical trials during which IFN-b was administered, either in combination with lopinavir-ritonavir and ribavirin (2) or alone in a nebulized, inhaled form of the molecule (3). Recombinant IFN-b therapy, in combination with lopinavir-ritonavir, was also associated with reduced mortality in a recently completed randomized clinical trial of hospitalized patients with Middle East respiratory syndrome (MERS) (4). These reports provide a rationale for IFN-b therapy of coronavirus infections associated with acute respiratory syndromes, together with the finding of an impaired type I IFN signature in COVID-19 patients with severe disease (5) .

Notwithstanding these results, it should be emphasized that only a subpopulation of COVID-19 patients suffers from a defective type I IFN response (6) . Indeed, we show here that among 112 patients with COVID-19 hospitalized at the Pitié-Salpêtrière Hospital in Paris, France, only 35.7% had serum IFN-b levels below the limit of detection at admission (Fig. 1) . Moreover, circulating IFN-b levels, when detectable, were significantly higher in patients who died before day 30 than in survivors (mean, 1.79 versus 1.17 pg/ml; P = 0.02) (Fig. 1) . Mortality was higher (P = 0.01) in those patients (7 out of 11 patients; 63.6%) with the highest IFN-b levels (.3.4 pg/ml) than in patients with lower IFN-b levels (15 out of 61; 24.6%), as well as in those with IFN-b levels below the limit of detection (11 out of 40; 27.5%) (Fig. 1) .

These results might be important to consider in the context of an hyperinflammatory role for type I IFNs in cases of severe COVID-19 (7), as was demonstrated in coronavirus-infected mouse models (8, 9) and in a recently reported case of COVID-19-associated type I interferonopathy (10) . In this respect, the timing of IFN-b treatment for COVID-19 patients must be taken into account. Indeed, as shown by Davoudi-Monfared et al. (1) , IFN administration during the early phases of SARS-CoV-2 infection results in a favorable clinical outcome. In contrast, late administration ($5 days after admission) is associated with increased in-hospital mortality, most likely due to an exacerbation of the cytokine storm associated with COVID-19 (11).

Thus, IFN-b therapy might not be recommended for COVID-19 patients with high circulating type I IFN levels or more than 5 days after symptom onset. In addition, we

A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebocontrolled, phase 2 trial

Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Saudi Critical Care Trials Group. 2020. Interferon beta-1b and lopinavir-ritonavir for Middle East FIG 1 IFN-b levels among healthy controls and COVID-19 patients. Patients (n = 112) presenting with a positive SARS-CoV-2 real-time reverse transcriptase-PCR result from their nasopharyngeal swab and pulmonary involvement were included at hospital admission. Mortality was assessed at day 30 after admission. Sampling times from onset of symptoms varied between 0 and 25 days (median, 9 days). Healthy SARS-CoV-2-negative individuals (n = 10) were included as controls. For all individuals, sera were stored less than 4 h after collection at 280°C. Serum IFN-b levels were measured by a highly sensitive enzyme-linked immunosorbent assay (ELISA; VeriKine-HS human IFN-b ELISA kit

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice

Covid-19-associated myopathy caused by type I interferonopathy

Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients

Autoantibodies against type I IFNs in patients with life-threatening COVID-19